Fig. 3: Antibody responses in patients with CLL following second Covid-19 vaccine.

A Antibody responses to SARS-CoV-2 Spike following second vaccine in sera from healthy donors (HD) and patients with CLL, as measured by Roche assay. No donors had evidence of previous exposure (cut off for positivity at 0.8 indicated by dotted line). B Dot plot of antibody responses to SARS-CoV-2 Spike in patient with CLL following second vaccine, by management stage is shown, (W+W watch and wait; PCi previous chemo-immunotherapy but not on active therapy) as measured by Roche. C Bar chart to show the percentage response after second vaccine in HD and CLL measured by Roche. D Antibody responses to SARS-CoV-2 spike following second vaccine in healthy donors (HD) and patients with CLL, as measured by TBS assay (cut off for positivity indicated by the dotted line at a ratio of 1). E Antibody responses to SARS-CoV-2 Spike in patient with CLL following second vaccine, by management stage, DBS testing and analysed by TBS assay (Kruskal–Wallis p < 0.0045 and Dunn’s analysis for BTKi therapy and W+W p = 0.03). Watch and Wait (W+W); Previous Chemo-immunotherapy but not on active therapy (pCI); Bruton Tyrosine Kinase therapy (BTKi); Treatment planned (TP). F Bar chart to show the percentage response after second vaccine in HD and CLL measured by TBS assay using DBS eluates.